Overview

FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

Status:
Recruiting
Trial end date:
2022-07-03
Target enrollment:
Participant gender:
Summary
A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
Phase:
Phase 2
Details
Lead Sponsor:
Future Medicine